The collaboration combines Shaare Zedek’s real-world data and clinical expertise with Imagene AI’s Oncology Intelligence Suite to advance biomarker discovery and accelerate precision cancer care.
October 29, 2025 [NewsWire]
Imagene AI, a pioneer in multimodal foundation models for precision oncology, and Shaare Zedek Scientific, the innovation arm of Shaare Zedek Medical Center, today announced a strategic collaboration to advance cancer research and personalized care with multimodal AI and real-world data.
The collaboration brings together Shaare Zedek’s real-world data, clinical research, and advanced digital infrastructure with Imagene AI’s Cross-Modality Intelligence Engine and OI Suite platform. The partnership aims to accelerate biomarker discovery, enable multimodal translational research, and support more precise and timely treatment decisions.
haare Zedek Scientific will provide Imagene AI access to de-identified multimodal, longitudinal data to enrich Imagene AI’s proprietary real-world data lake. This will enrich Imagene AI’s proprietary real-world data lake. Shaare Zedek’s researchers and clinicians will gain access to OI Suite to independently analyze multimodal datasets, generate biomarker hypotheses, and develop predictive models across cancer types. The platform also enables users to explore explainable AI outputs such as region-level heatmaps and histological features in a secure, no-code environment.
“This collaboration strengthens our mission to transform oncology research through real-world data and AI,” said Dean Bitan, Co-founder and CEO of Imagene AI. “Together with Shaare Zedek, we are expanding the frontiers of discovery, making multimodal intelligence accessible to researchers and bringing precision oncology closer to patients.”
Real-world data is a critical foundation for advancing AI-powered oncology research. By continuously expanding its proprietary real-world data lake, Imagene AI is strengthening the infrastructure that supports multimodal discovery, biomarker development, and translational research across cancer types. The company recently launched the OI Suite Discovery Program, offering complimentary access for biopharma teams to accelerate discovery and precision oncology.